Suppr超能文献

遗传性血色素沉着症:基因发现及其对人群筛查的意义。

Hereditary hemochromatosis: gene discovery and its implications for population-based screening.

作者信息

Burke W, Thomson E, Khoury M J, McDonnell S M, Press N, Adams P C, Barton J C, Beutler E, Brittenham G, Buchanan A, Clayton E W, Cogswell M E, Meslin E M, Motulsky A G, Powell L W, Sigal E, Wilfond B S, Collins F S

机构信息

Department of Medicine, University of Washington, Seattle 98105, USA.

出版信息

JAMA. 1998 Jul 8;280(2):172-8. doi: 10.1001/jama.280.2.172.

Abstract

OBJECTIVE

To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers.

PARTICIPANTS

An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information.

EVIDENCE

The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder.

CONSENSUS PROCESS

Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period.

CONCLUSIONS

Genetic testing is not recommended at this time in population-based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype-phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.

摘要

目的

评估基因检测在遗传性血色素沉着症筛查中的作用,以帮助指导临床医生、政策制定者和研究人员。

参与者

1997年3月3日,疾病控制与预防中心(CDC)和国家人类基因组研究所(NHGRI)召集了一个专家小组,小组成员在流行病学、遗传学、肝病学、铁过载疾病、分子生物学、公共卫生以及围绕遗传信息发现和使用的伦理、法律及社会影响等方面具有专业知识。

证据

该小组审查了有关血色素沉着症临床表现、自然病史和遗传学的证据,包括目前关于血色素沉着症候选基因(HFE)的数据以及针对该疾病进行基因检测的伦理和健康政策影响。

共识过程

通过小组讨论并经口头表决确认达成共识。共识声明草案由一个撰写委员会起草,随后在1年时间里由专家小组的所有成员进行审查和修订。

结论

由于HFE突变的患病率和外显率以及携带HFE突变的无症状人群的最佳治疗存在不确定性,目前不建议在基于人群的遗传性血色素沉着症筛查中进行基因检测。此外,使用基因筛查检测引发了对可能的污名化和歧视的担忧。HFE突变检测可能在确诊血清铁水平升高的人群遗传性血色素沉着症中发挥作用,但即使这种用途也受到基因型与表型相关性不确定性的限制。为解决这些问题,专家小组高度重视基于人群的研究,以确定HFE突变的患病率、不同HFE基因型的年龄和性别相关外显率、HFE基因型与环境修饰因素之间的相互作用以及血色素沉着症基因筛查的心理社会结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验